Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NewAmsterdam Pharma Company N.V. - Ordinary Shares
(NQ:
NAMS
)
34.51
-0.77 (-2.17%)
Streaming Delayed Price
Updated: 12:27 PM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NewAmsterdam Pharma Company N.V. - Ordinary Shares
< Previous
1
2
3
4
5
6
Next >
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
November 25, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million
↗
November 20, 2025
Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
↗
November 20, 2025
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Gets Booted in Latest Fund Update
↗
November 19, 2025
Bain Capital sold its entire stake in Nuvalent stock during the third quarter.
Via
The Motley Fool
Topics
Regulatory Compliance
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock
↗
November 19, 2025
Bain Capital completely exited its position in Disc Medicine stock during the third quarter
Via
The Motley Fool
Why Bain Capital Is Selling Shares of This Biotech Stock Now
↗
November 18, 2025
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.
Via
The Motley Fool
Topics
Regulatory Compliance
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 07, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
November 05, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
October 30, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings)
↗
October 20, 2025
Via
Benzinga
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
September 24, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts
↗
August 25, 2025
Via
Benzinga
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
August 25, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
August 18, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co
↗
August 07, 2025
Via
Benzinga
NewAmsterdam (NAMS) Q2 Revenue Jumps 49%
↗
August 06, 2025
Via
The Motley Fool
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 06, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
July 30, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
July 22, 2025
– NewAmsterdam to host conference call at 10:00 a.m. ET on Wednesday, July 30th –
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
What Analysts Are Saying About NewAmsterdam Pharma Co Stock
↗
June 12, 2025
Via
Benzinga
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib
↗
June 09, 2025
NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.
Via
Benzinga
Get insights into the top gainers and losers of Monday's pre-market session.
↗
June 09, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
June 09, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
June 05, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
May 27, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
May 14, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
May 08, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
May 07, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
